Sonoma Pharmaceuticals In... (SNOA)
3.30
-0.18 (-5.17%)
At close: Mar 24, 2025, 3:59 PM
3.15
-4.55%
After-hours: Mar 24, 2025, 07:57 PM EDT
-5.17% (1D)
| Bid | 3.15 |
| Market Cap | 5.33M |
| Revenue (ttm) | 15.42M |
| Net Income (ttm) | -4.14M |
| EPS (ttm) | -2.26 |
| PE Ratio (ttm) | -1.46 |
| Forward PE | -2.28 |
| Analyst | n/a |
| Ask | 3.33 |
| Volume | 126,653 |
| Avg. Volume (20D) | 1,634,017 |
| Open | 3.50 |
| Previous Close | 3.48 |
| Day's Range | 3.12 - 3.62 |
| 52-Week Range | 1.90 - 9.40 |
| Beta | 1.56 |
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; ...
Sector Healthcare
IPO Date Jan 25, 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol SNOA
Website https://www.sonomapharma.com
Next Earnings Release
Sonoma Pharmaceuticals Inc. is scheduled to release its earnings on Jun 16, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+21.86%
Sonoma Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
2 weeks ago
+40.2%
Sonoma Pharmaceuticals shares are trading higher after the company announced it secured UK regulatory clearances for its key wound care and dermatology products.
1 month ago · accessnewswire.com
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2025 Financial ResultsRevenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net lo...